Aberdeen Group plc Has $5.96 Million Holdings in ProQR Therapeutics N.V. $PRQR

Key Points

• Aberdeen Group plc boosted its stake in ProQR by 28.4% to 2,950,676 shares (about 2.8% of the company), valued at roughly $5.96 million at the end of the quarter.
• Analyst sentiment is a Moderate Buy (six Buys, one Hold, one Sell) with a consensus price target of $6.80, and Oppenheimer recently started coverage with an Outperform rating and a $9.00 target.
• ProQR reported Q results with EPS of ($0.09) missing estimates and revenue of $5.53M versus $6.12M expected; the stock trades around $1.83 with a market cap near $192.8M and negative net margins.

Aberdeen Group plc increased its holdings in ProQR Therapeutics N.V. (NASDAQ:PRQR - Free Report) by 28.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,950,676 shares of the biopharmaceutical company's stock after acquiring an additional 651,853 shares during the period. Aberdeen Group plc owned about 2.80% of ProQR Therapeutics worth $5,960,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Moody Lynn & Lieberson LLC bought a new position in shares of ProQR Therapeutics during the 4th quarter valued at approximately $50,000. Palo Alto Investors LP bought a new position in ProQR Therapeutics in the 3rd quarter valued at $402,000. Citadel Advisors LLC boosted its holdings in ProQR Therapeutics by 73.2% in the 3rd quarter. Citadel Advisors LLC now owns 657,012 shares of the biopharmaceutical company's stock valued at $1,399,000 after purchasing an additional 277,749 shares during the period. Boothbay Fund Management LLC raised its position in shares of ProQR Therapeutics by 10.8% during the 3rd quarter. Boothbay Fund Management LLC now owns 248,290 shares of the biopharmaceutical company's stock valued at $529,000 after buying an additional 24,160 shares in the last quarter. Finally, ArrowMark Colorado Holdings LLC raised its position in shares of ProQR Therapeutics by 3.9% during the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,246,234 shares of the biopharmaceutical company's stock valued at $2,654,000 after buying an additional 46,596 shares in the last quarter. Hedge funds and other institutional investors own 32.65% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently commented on PRQR. Wall Street Zen upgraded shares of ProQR Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Saturday, March 14th. Weiss Ratings reiterated a "sell (d-)" rating on shares of ProQR Therapeutics in a research report on Thursday, January 22nd. Citigroup reissued a "market outperform" rating on shares of ProQR Therapeutics in a report on Friday, March 13th. Finally, Oppenheimer started coverage on shares of ProQR Therapeutics in a report on Thursday, March 12th. They issued an "outperform" rating and a $9.00 price target on the stock. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, ProQR Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $6.80.

ProQR Therapeutics Price Performance

NASDAQ:PRQR opened at $1.83 on Thursday. ProQR Therapeutics N.V. has a one year low of $1.07 and a one year high of $3.10. The company's 50-day simple moving average is $1.60 and its 200 day simple moving average is $1.99. The firm has a market capitalization of $192.81 million, a P/E ratio of -3.98 and a beta of 0.10.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last issued its earnings results on Thursday, March 12th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.01). ProQR Therapeutics had a negative return on equity of 65.89% and a negative net margin of 255.83%.The firm had revenue of $5.53 million during the quarter, compared to the consensus estimate of $6.12 million. On average, equities research analysts expect that ProQR Therapeutics N.V. will post -0.31 earnings per share for the current fiscal year.

ProQR Therapeutics Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company's pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.

Want to see what other hedge funds are holding PRQR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ProQR Therapeutics N.V. (NASDAQ:PRQR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.